Papers/PMID:41073637
Association of magnesium sulphate use with mortality in patients with acute respiratory distress syndrome: a retrospective propensity score-matched cohort study.
Scientific reports2025The record
3 findings · 1 compound · 3 endpoints
What it reported
How to read these marksWhat moved
3 findings
magnesium(2+) — decreases all-cause mortality
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×5“Magnesium sulphate use was associated with lower ICU 30-day all-cause mortality rates (HR, 0.75; 95% CI, 0.62–0.90; P = 0.002) (Table 2).”
Quoted verbatim from Association of magnesium sulphate use with mortality in patients with acute respiratory distress syndrome: a retrospective propensity score-matched cohort study.. - Study
- cohort
- Duration
- 4 weeks
- Dose
- intravenous magnesium sulphate during ICU stay; total dose mainly 1-10 g
- Population
- Adult ICU patients with ARDS in the MIMIC-IV database, propensity-score-matched cohort of magnesium sulphate users against non-users; horizon is ICU 30-day
Effect 0.75 hazard ratio, 95% CI 0.62 to 0.9
Association of magnesium sulphate use with mortality in patients with acute respiratory distress syndrome: a retrospective propensity score-matched cohort study.2025PMID:41073637Permalink
magnesium(2+) — increases hospital length of stay
LimitedEvidence strength: limited. Human evidence with several recorded weaknesses, or a design that tops out at limited.Finding“Magnesium sulphate use was associated with prolonged ICU stay (β, 2.05; 95% CI, 1.40–2.70; P < 0.001) and hospital stay (β, 2.21; 95% CI, 0.87–3.56; P = 0.001) (Table 2).”
Quoted verbatim from Association of magnesium sulphate use with mortality in patients with acute respiratory distress syndrome: a retrospective propensity score-matched cohort study.. - Study
- cohort
- Dose
- intravenous magnesium sulphate during ICU stay; total dose mainly 1-10 g
- Population
- Adult ICU patients with ARDS in the MIMIC-IV database, propensity-score-matched cohort of magnesium sulphate users against non-users
Association of magnesium sulphate use with mortality in patients with acute respiratory distress syndrome: a retrospective propensity score-matched cohort study.2025PMID:41073637Permalink
magnesium(2+) — increases intensive care unit length of stay
LimitedEvidence strength: limited. Human evidence with several recorded weaknesses, or a design that tops out at limited.Finding“Magnesium sulphate use was associated with prolonged ICU stay (β, 2.05; 95% CI, 1.40–2.70; P < 0.001) and hospital stay (β, 2.21; 95% CI, 0.87–3.56; P = 0.001) (Table 2).”
Quoted verbatim from Association of magnesium sulphate use with mortality in patients with acute respiratory distress syndrome: a retrospective propensity score-matched cohort study.. - Study
- cohort
- Dose
- intravenous magnesium sulphate during ICU stay; total dose mainly 1-10 g
- Population
- Adult ICU patients with ARDS in the MIMIC-IV database, propensity-score-matched cohort of magnesium sulphate users against non-users
Association of magnesium sulphate use with mortality in patients with acute respiratory distress syndrome: a retrospective propensity score-matched cohort study.2025PMID:41073637Permalink